Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208104 | 0.77 | EGLN1 (0.62) | FTOEGFREGLN1EGLN3KDM4C | |
| SCHEMBL5030186 | 0.74 | KDM4C (0.45) | FTOEGFREGLN1EGLN2EGLN3 | |
| SCHEMBL18496406 | 0.73 | EGLN1 (0.47) | FTOEGLN1EGLN2KDM4C | |
| SCHEMBL522835 | 0.73 | EGLN1 (0.66) | FTOEGLN1EGLN2EGLN3 | |
| SCHEMBL30274444 | 0.71 | EGLN1 (0.77) | FTOEGLN1EGLN2 | |
| SCHEMBL522924 | 0.71 | EGLN1 (0.77) | FTOEGLN1EGLN2 | |
| SCHEMBL523031 | 0.71 | EGLN1 (0.55) | FTOEGLN1EGLN2EGLN3 | |
| SCHEMBL1219368 | 0.70 | CHRNA7 (0.48) | FTOEGFREGLN1EGLN3KDM4C | |
| SCHEMBL522832 | 0.70 | EGLN1 (0.64) | EGLN1EGLN2 | |
| SCHEMBL2959148 | 0.68 | EGLN1 (0.47) | FTOEGFREGLN1EGLN3KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016056-A1 | TOPICAL AND TRANSDERMAL DELIVERY OF HIF-1 MODULATORS TO PREVENT AND TREAT CHRONIC WOUNDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-01-20 | — | — | US | disclosed |
| US-11160775-B2 | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200338024-A1 | TOPICAL AND TRANSDERMAL DELIVERY OF HIF-1 MODULATORS TO PREVENT AND TREAT CHRONIC WOUNDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| US-10751304-B2 | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10548860-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190192452-A1 | HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-10220009-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-20190008807-A1 | TOPICAL AND TRANSDERMAL DELIVERY OF HIF-1 MODULATORS TO PREVENT AND TREAT CHRONIC WOUNDS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-01-10 | — | — | US | disclosed |
| US-10098857-B2 | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170281570-A1 | TOPICAL AND TRANSDERMAL DELIVERY OF HIF-1 MODULATORS TO PREVENT AND TREAT CHRONIC WOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-05 | — | — | US | disclosed |
| US-20170252310-A9 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-07 | — | — | US | disclosed |
| US-20160184244-A1 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes | UNIV LELAND STANFORD JUNIOR (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150196512-A1 | HIF-1 Modulator Paint Formulation and Uses Thereof | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-20140370078-A1 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2014-12-18 | — | — | US | disclosed |
| WO-2014100233-A1 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE DURING REJECTION EPISODES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014036414-A2 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20100092546-A1 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-04-15 | — | — | US | disclosed |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2008-09-04 | — | — | US | disclosed |
| WO-2006084210-A9 | HIF MODULATING COMPOUNDS AND METHODS OF USE THEREOF | UNIV CALIFORNIA SAN DIEGO (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006084210-A2 | HIF MODULATING COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | HIF1A, HIF1AN, EGLN3 | FTO 3699/4885EGFR 3931/4885EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.